0001140361-15-016864.txt : 20150429
0001140361-15-016864.hdr.sgml : 20150429
20150429174436
ACCESSION NUMBER: 0001140361-15-016864
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150427
FILED AS OF DATE: 20150429
DATE AS OF CHANGE: 20150429
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hager Alicia J.
CENTRAL INDEX KEY: 0001553354
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 15814309
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc1.xml
FORM 4
X0306
4
2015-04-27
0
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001553354
Hager Alicia J.
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
VP & General Counsel
Common Stock
2015-04-27
4
M
0
1800
3.42
A
16800
D
Common Stock
2015-04-27
4
S
0
945
25.164
D
15855
D
Common Stock
2015-04-27
4
S
0
855
26.1898
D
15000
D
Stock Option (Right to Buy)
3.42
2015-04-27
4
M
0
1800
0.00
D
2018-07-22
Common Stock
1800
19252
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 23, 2015.
Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
This transaction was executed in multiple trades in prices ranging from $24.90 to $25.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $26.00 to $26.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.
/s/ Alicia J. Hager
2015-04-29